United Therapeutics, Novartis Settle Dispute Over Generic Remodulin
September 30 2015 - 9:57AM
Dow Jones News
By Tess Stynes
United Therapeutics Corp. (UTHR) on Wednesday said it agreed to
grant to Novartis AG's (NVS) Sandoz Inc. unit a nonexclusive
license to sell a generic version of the biotechnology company's
hypertension drug Remodulin by June 2018.
The agreement ends a long-running dispute between the two
companies, both of which also agreed to end all pending litigation.
American depositary shares of Novartis rose 2.9% in recent
premarket trading.
Sandoz could be permitted to enter the market sooner under
certain circumstances, United Therapeutics said in a news
release.
The license excludes other United Therapeutics products, as well
as technology related to an implantable version of Remodulin that
United Therapeutics is developing with medical-device maker
Medtronic PLC (MDT) and a pre-filled semi-disposable pump system
being developed with DEKA Research & Development Corp.
United Therapeutics last year won a partial victory in its
patent battle with Sandoz, when a federal judge ruled that Sandoz's
generic drug application would infringe one of the patents in the
legal dispute, potentially protecting Remodulin from generic
competition until the second half of 2017.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 30, 2015 09:42 ET (13:42 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Medtronic (NYSE:MDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2023 to Sep 2024